These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

197 related items for PubMed ID: 11553026

  • 1. Elevated serum endogenous inhibitor of nitric oxide synthase and endothelial dysfunction in aged rats.
    Xiong Y, Yuan LW, Deng HW, Li YJ, Chen BM.
    Clin Exp Pharmacol Physiol; 2001 Oct; 28(10):842-7. PubMed ID: 11553026
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Relationship between protective effects of rosiglitazone on endothelium and endogenous nitric oxide synthase inhibitor in streptozotocin-induced diabetic rats and cultured endothelial cells.
    Wang S, Jiang JL, Hu CP, Zhang XJ, Yang DL, Li YJ.
    Diabetes Metab Res Rev; 2007 Feb; 23(2):157-64. PubMed ID: 16770837
    [Abstract] [Full Text] [Related]

  • 4. Elevation of an endogenous inhibitor of nitric oxide synthesis in experimental congestive heart failure.
    Feng Q, Lu X, Fortin AJ, Pettersson A, Hedner T, Kline RL, Arnold JM.
    Cardiovasc Res; 1998 Mar; 37(3):667-75. PubMed ID: 9659450
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Probucol preserves endothelial function by reduction of the endogenous nitric oxide synthase inhibitor level.
    Jiang JL, Li Ns NS, Li YJ, Deng HW.
    Br J Pharmacol; 2002 Mar; 135(5):1175-82. PubMed ID: 11877324
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Epigallocatechin gallate preserves endothelial function by reducing the endogenous nitric oxide synthase inhibitor level.
    Tang WJ, Hu CP, Chen MF, Deng PY, Li YJ.
    Can J Physiol Pharmacol; 2006 Feb; 84(2):163-71. PubMed ID: 16900942
    [Abstract] [Full Text] [Related]

  • 9. Effect of simvastatin on endothelium-dependent vaso-relaxation and endogenous nitric oxide synthase inhibitor.
    Jiang JL, Jiang DJ, Tang YH, Li NS, Deng HW, Li YJ.
    Acta Pharmacol Sin; 2004 Jul; 25(7):893-901. PubMed ID: 15210062
    [Abstract] [Full Text] [Related]

  • 10. Aspirin protected against endothelial damage induced by LDL: role of endogenous NO synthase inhibitors in rats.
    Deng S, Deng PY, Jiang JL, Ye F, Yu J, Yang TL, Deng HD, Li YJ.
    Acta Pharmacol Sin; 2004 Dec; 25(12):1633-9. PubMed ID: 15569408
    [Abstract] [Full Text] [Related]

  • 11. Elevated levels of the serum endogenous inhibitor of nitric oxide synthase and metabolic control in rats with streptozotocin-induced diabetes.
    Xiong Y, Fu YF, Fu SH, Zhou HH.
    J Cardiovasc Pharmacol; 2003 Aug; 42(2):191-6. PubMed ID: 12883321
    [Abstract] [Full Text] [Related]

  • 12. Effect of diabetic duration on serum concentrations of endogenous inhibitor of nitric oxide synthase in patients and rats with diabetes.
    Xiong Y, Lei M, Fu S, Fu Y.
    Life Sci; 2005 May 27; 77(2):149-59. PubMed ID: 15862600
    [Abstract] [Full Text] [Related]

  • 13. Asymmetric dimethylarginine (ADMA) induces vascular endothelium impairment and aggravates post-ischemic ventricular dysfunction in rats.
    De Gennaro Colonna V, Bonomo S, Ferrario P, Bianchi M, Berti M, Guazzi M, Manfredi B, Muller EE, Berti F, Rossoni G.
    Eur J Pharmacol; 2007 Feb 28; 557(2-3):178-85. PubMed ID: 17258196
    [Abstract] [Full Text] [Related]

  • 14. Angiotensin-converting enzyme inhibition and angiotensin AT1-receptor antagonism equally improve endothelial vasodilator function in L-NAME-induced hypertensive rats.
    De Gennaro Colonna V, Rigamonti A, Fioretti S, Bonomo S, Manfredi B, Ferrario P, Bianchi M, Berti F, Muller EE, Rossoni G.
    Eur J Pharmacol; 2005 Jun 15; 516(3):253-9. PubMed ID: 15963975
    [Abstract] [Full Text] [Related]

  • 15. Pioglitazone, a PPARgamma agonist, restores endothelial function in aorta of streptozotocin-induced diabetic rats.
    Majithiya JB, Paramar AN, Balaraman R.
    Cardiovasc Res; 2005 Apr 01; 66(1):150-61. PubMed ID: 15769458
    [Abstract] [Full Text] [Related]

  • 16. Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocyst(e)inemia or hypercholesterolemia.
    Böger RH, Bode-Böger SM, Sydow K, Heistad DD, Lentz SR.
    Arterioscler Thromb Vasc Biol; 2000 Jun 01; 20(6):1557-64. PubMed ID: 10845872
    [Abstract] [Full Text] [Related]

  • 17. Protective effects of ACE inhibitors on vascular endothelial dysfunction induced by exogenous advanced oxidation protein products in rats.
    Chen SX, Song T, Zhou SH, Liu YH, Wu SJ, Liu LY.
    Eur J Pharmacol; 2008 Apr 28; 584(2-3):368-75. PubMed ID: 18334254
    [Abstract] [Full Text] [Related]

  • 18. Increased (E)-4-hydroxy-2-nonenal and asymmetric dimethylarginine concentrations and decreased nitric oxide concentrations in the plasma of patients with major depression.
    Selley ML.
    J Affect Disord; 2004 Jun 28; 80(2-3):249-56. PubMed ID: 15207938
    [Abstract] [Full Text] [Related]

  • 19. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia.
    Böger RH, Bode-Böger SM, Szuba A, Tsao PS, Chan JR, Tangphao O, Blaschke TF, Cooke JP.
    Circulation; 1998 Nov 03; 98(18):1842-7. PubMed ID: 9799202
    [Abstract] [Full Text] [Related]

  • 20. Increased symmetrical dimethylarginine in ischemic acute kidney injury as a causative factor of renal L-arginine deficiency.
    Betz B, Möller-Ehrlich K, Kress T, Kniepert J, Schwedhelm E, Böger RH, Wanner C, Sauvant C, Schneider R.
    Transl Res; 2013 Aug 03; 162(2):67-76. PubMed ID: 23707198
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.